Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis.

Abstract

To clarify how intravenous immunoglobulin (IVIg) acts on Guillain-Barré syndrome, we investigated the effects of intact-type IVIg treatment on experimental allergic neuritis (EAN) induced by immunizing with synthetic peptide from bovine P2 protein. Treatment with intact-type IVIg (400 mg/kg/day) on days 0, 7, 14, 15 and 16 after immunization prevented the paralysis, whereas treatment with F(ab')2 failed to alter the clinical course. Intact-type IVIg treatment given on days 0 and 1 showed almost the same efficacy. These results suggest that intact-type IVIg is superior to F(ab')2 in ameliorating the clinical course of EAN and that the Fc portion might affect the immune system.

• Authors: F Miyagi, H Horiuchi, I Nagata, S Kitahara, M Kiyoki, K Komoriya, N Yuki
• Journal: Journal of neuroimmunology (J Neuroimmunol) Vol. 78 Issue 1-2 Pg. 127-31 (Sep 1997) ISSN: 0165-5728 [Print] Netherlands
• PMID: 9307236 (Publication Type: Journal Article)

Chemical References

• Antibodies
• Immunoglobulin Fc Fragments
• Immunoglobulins, Intravenous
• Myelin P2 Protein
• Peptide Fragments

Topics

• Animals
• Antibodies (analysis)
• Cattle
• Immunization
• Immunoglobulin Fc Fragments (immunology, therapeutic use)
• Immunoglobulins, Intravenous (immunology, therapeutic use)
• Male
• Myelin P2 Protein (immunology)
• Neuritis, Autoimmune, Experimental (immunology, therapy)
• Peptide Fragments (immunology)
• Rats
• Rats, Inbred Lew